Huntington’s disease (HD) arises from the abnormal expansion of CAG repeats in the huntingtin gene (HTT), resulting in the production of the mutant huntingtin protein (mHTT) with a polyglutamine stretch in its N-terminus. The pathogenic mechanisms underlying HD are complex and not yet fully elucidated. However, mHTT forms aggregates and accumulates abnormally in neuronal nuclei and processes, leading to disruptions in multiple cellular functions. Although there is currently no effective curative treatment for HD, significant progress has been made in developing various therapeutic strategies to treat HD. In addition to drugs targeting the neuronal toxicity of mHTT, gene therapy approaches that aim to reduce the expression of the mutant HTT gene hold great promise for effective HD therapy. This review provides an overview of current HD treatments, discusses different therapeutic strategies, and aims to facilitate future therapeutic advancements in the field.
Huntington’s disease (HD) is a hereditary neurodegenerative disorder caused by a CAG tract expansion in the huntingtin gene (HTT). HD is characterized by involuntary movements, cognitive decline, and behavioral changes. Pathologically, patients with HD show selective striatal neuronal vulnerability at the early disease stage, although the mutant protein is ubiquitously expressed. Activation of the immune system and glial cell-mediated neuroinflammatory responses are early pathological features and have been found in all neurodegenerative diseases (NDDs), including HD. However, the role of inflammation in HD, as well as its therapeutic significance, has been less extensively studied compared to other NDDs. This review highlights the significantly elevated levels of inflammatory proteins and cellular markers observed in various HD animal models and HD patient tissues, emphasizing the critical roles of microglia, astrocytes, and oligodendrocytes in mediating neuroinflammation in HD. Moreover, it expands on recent discoveries related to the peripheral immune system’s involvement in HD. Although current immunomodulatory treatments and inflammatory biomarkers for adjunctive diagnosis in HD are limited, targeting inflammation in combination with other therapies, along with comprehensive personalized treatment approaches, shows promising therapeutic potential.
Powered by the increasing demand for environmental protection, GSCM (Green Supply Chain Management) has received mushrooming amount of attention. In this dissertation, GSCM is clustered based on PEST, and thereafter analyzed by bibliometric and literature research. This dissertation reviews literature from eight perspectives such as carbon tax, carbon cap, circular economy, economic model, environmental awareness, green cooperation, green packaging, and green transportation. Eventually, the dissertation puts forward the analysis of the prospect of GSCM based on the conclusion after the review.
Tau pathology is a hallmark feature of Alzheimer’s disease (AD) and is tightly associated with clinical manifestations. No disease-modifying therapy is currently available for AD, partly due to prominent interspecies differences in tau expression patterns between rodents and primates. To facilitate the investigation of primate-specific tau pathology, we developed an in vitro platform using monkey (Macaca fascicularis) brain slice cultures (BSC) that preserve native three-dimensional tissue architecture and maintain functional networks closely mirroring in vivo conditions. We systematically evaluated various adeno-associated virus (AAV) serotypes and promoter combinations to achieve efficient transgenic tau expression. Our data confirm that the monkey BSC system is highly amenable to AAV-mediated gene delivery, exhibiting robust transduction of glial cells with minimal cytotoxicity and allowing for the examination of glial pathology induced by disease-associated proteins. Notably, this platform is applicable to both juvenile and aged specimens, enabling comparative analyses of age-dependent susceptibility to pathological insults. Following overexpression of mutant human tau, we observed time-dependent tau pathology development within 2–4 weeks post-infection, including hyperphosphorylation and aggregation. This in vitro primate model offers a unique opportunity to dissect primate-specific pathological events. Furthermore, the scalability and reproducibility of this system render it ideally suited for drug screening, providing a more translationally relevant preclinical bridge between rodent models and human clinical trials.